136 related articles for article (PubMed ID: 26117456)
1. Keap1-Nrf2 signalling in pancreatic cancer.
Hayes AJ; Skouras C; Haugk B; Charnley RM
Int J Biochem Cell Biol; 2015 Aug; 65():288-99. PubMed ID: 26117456
[TBL] [Abstract][Full Text] [Related]
2. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer.
Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
[TBL] [Abstract][Full Text] [Related]
3. Nrf2: friend or foe for chemoprevention?
Kensler TW; Wakabayashi N
Carcinogenesis; 2010 Jan; 31(1):90-9. PubMed ID: 19793802
[TBL] [Abstract][Full Text] [Related]
4. Glutamine antagonists may KEAP lung cancer in check.
Blatt EB; DeBerardinis RJ
Sci Adv; 2024 Mar; 10(13):eado7808. PubMed ID: 38536918
[TBL] [Abstract][Full Text] [Related]
5. Roles of Nrf2 in cell proliferation and differentiation.
Murakami S; Motohashi H
Free Radic Biol Med; 2015 Nov; 88(Pt B):168-178. PubMed ID: 26119783
[TBL] [Abstract][Full Text] [Related]
6. The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic.
O'Connell MA; Hayes JD
Biochem Soc Trans; 2015 Aug; 43(4):687-9. PubMed ID: 26551713
[TBL] [Abstract][Full Text] [Related]
7. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer.
Chio IIC; Jafarnejad SM; Ponz-Sarvise M; Park Y; Rivera K; Palm W; Wilson J; Sangar V; Hao Y; Öhlund D; Wright K; Filippini D; Lee EJ; Da Silva B; Schoepfer C; Wilkinson JE; Buscaglia JM; DeNicola GM; Tiriac H; Hammell M; Crawford HC; Schmidt EE; Thompson CB; Pappin DJ; Sonenberg N; Tuveson DA
Cell; 2016 Aug; 166(4):963-976. PubMed ID: 27477511
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.
Tebay LE; Robertson H; Durant ST; Vitale SR; Penning TM; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2015 Nov; 88(Pt B):108-146. PubMed ID: 26122708
[TBL] [Abstract][Full Text] [Related]
9. The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance.
Furfaro AL; Traverso N; Domenicotti C; Piras S; Moretta L; Marinari UM; Pronzato MA; Nitti M
Oxid Med Cell Longev; 2016; 2016():1958174. PubMed ID: 26697129
[TBL] [Abstract][Full Text] [Related]
10. Effects of different exercise durations on Keap1-Nrf2-ARE pathway activation in mouse skeletal muscle.
Li T; He S; Liu S; Kong Z; Wang J; Zhang Y
Free Radic Res; 2015 Oct; 49(10):1269-74. PubMed ID: 26118597
[TBL] [Abstract][Full Text] [Related]
11. The complexity of the Nrf2 pathway: beyond the antioxidant response.
Huang Y; Li W; Su ZY; Kong AN
J Nutr Biochem; 2015 Dec; 26(12):1401-13. PubMed ID: 26419687
[TBL] [Abstract][Full Text] [Related]
12. Inflammation-induced ROS generation causes pancreatic cell death through modulation of Nrf2/NF-κB and SAPK/JNK pathway.
Choudhury S; Ghosh S; Gupta P; Mukherjee S; Chattopadhyay S
Free Radic Res; 2015; 49(11):1371-83. PubMed ID: 26189548
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of the Keap1-Nrf2 pathway in cancer.
Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
Biochem Soc Trans; 2015 Aug; 43(4):645-9. PubMed ID: 26551706
[TBL] [Abstract][Full Text] [Related]
14. Nrf2 facilitates repair of radiation induced DNA damage through homologous recombination repair pathway in a ROS independent manner in cancer cells.
Jayakumar S; Pal D; Sandur SK
Mutat Res; 2015 Sep; 779():33-45. PubMed ID: 26133502
[TBL] [Abstract][Full Text] [Related]
15. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Daemen A; Peterson D; Sahu N; McCord R; Du X; Liu B; Kowanetz K; Hong R; Moffat J; Gao M; Boudreau A; Mroue R; Corson L; O'Brien T; Qing J; Sampath D; Merchant M; Yauch R; Manning G; Settleman J; Hatzivassiliou G; Evangelista M
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4410-7. PubMed ID: 26216984
[TBL] [Abstract][Full Text] [Related]
16. The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma.
Krah NM; De La O JP; Swift GH; Hoang CQ; Willet SG; Chen Pan F; Cash GM; Bronner MP; Wright CV; MacDonald RJ; Murtaugh LC
Elife; 2015 Jul; 4():. PubMed ID: 26151762
[TBL] [Abstract][Full Text] [Related]
17. The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism.
Chambel SS; Santos-Gonçalves A; Duarte TL
Biomed Res Int; 2015; 2015():597134. PubMed ID: 26120584
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention.
Harder B; Jiang T; Wu T; Tao S; Rojo de la Vega M; Tian W; Chapman E; Zhang DD
Biochem Soc Trans; 2015 Aug; 43(4):680-6. PubMed ID: 26551712
[TBL] [Abstract][Full Text] [Related]
19. Keap1/Nrf2 pathway in the frontiers of cancer and non-cancer cell metabolism.
Chartoumpekis DV; Wakabayashi N; Kensler TW
Biochem Soc Trans; 2015 Aug; 43(4):639-44. PubMed ID: 26551705
[TBL] [Abstract][Full Text] [Related]
20. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma.
Zhang M; Zhang C; Zhang L; Yang Q; Zhou S; Wen Q; Wang J
BMC Cancer; 2015 Jul; 15():531. PubMed ID: 26194347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
